Anteris Technologies Ltd (Anteris Technologies), formerly Admedus Ltd designs, develops, and commercializes innovative medical devices and technologies with a focus on tissue engineering and immunotherapies. The company's primary activities include conducting clinical trials, securing regulatory approvals, and manufacturing its flagship product, the DurAVR THV, a transcatheter heart valve (THV) for treating aortic stenosis. Anteris also collaborates with v2vmedtech inc to develop a minimally invasive treatment for mitral and tricuspid valve regurgitation. The DurAVR THV, made using Anteris' patented ADAPT anti-calcification tissue technology, is used by healthcare professionals in the treatment of severe aortic stenosis. The company's products are distributed globally. The company's target markets include Australia, Europe, the US, Canada, Singapore, Malaysia, India, Hong Kong, and the Middle East. Anteris Technologies is headquartered in Brisbane, Queensland, Australia.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Anteris Technologies Ltd
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Anteris Technologies Ltd Company Overview
Anteris Technologies Ltd Company Snapshot
Anteris Technologies Ltd Pipeline Products and Ongoing Clinical Trials Overview
Anteris Technologies Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Anteris Technologies Ltd, Recent Developments
Oct 17, 2024: Anteris Receives $1.4m R&D Tax Refund
Jul 01, 2024: Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study
Jun 20, 2024: DurAVR THV First-in-Human Data Confirms Optimal Valve Positioning with the ComASUR Delivery System
Jun 18, 2024: Anteris Provides Update on Pivotal Trial Submission US FDA has provided positive feedback on key elements of the study design
Jun 13, 2024: Anteris Provides Update on DurAVR THV Valve-In-Valve Experience Presented at New York Valves 2024
Jun 11, 2024: Anteris Provides Data Update on First in Human Study of DurAVR THV Presented at New York Valves 2024
Aug 14, 2023: Further clinical success for Anteris Technologies’ biomimetic heart valve
Aug 09, 2023: Anteris’ starts US trial for DurAVR transcatheter heart valve
Jul 31, 2023: Anteris Technologies Announces First Successful Implantation of DurAVR THV in a Valve-in-Valve Procedure
Jun 13, 2023: Latest Patient Group Show Best Results to Date at 30 Days
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Anteris Technologies Ltd Pipeline Products and Ongoing Clinical Trials Overview
Anteris Technologies Ltd Pipeline Products by Equipment Type
Anteris Technologies Ltd Pipeline Products by Indication
Anteris Technologies Ltd Ongoing Clinical Trials by Trial Status
Anteris Technologies Ltd, Key Facts
Anteris Technologies Ltd, Major Products and Services
Anteris Technologies Ltd Number of Pipeline Products by Development Stage
Anteris Technologies Ltd Pipeline Products Summary by Development Stage
Anteris Technologies Ltd Ongoing Clinical Trials by Trial Status